Revolution Medicines (RVMD) Q4 FY25 earnings call

Revolution Medicines reported significant progress in advancing its RAS(ON) inhibitor pipeline, with multiple registrational trials underway or planned across pancreatic cancer, NSCLC, and CRC. The company is also building out its commercialization capabilities in anticipation of potential product launches, while managing increased operating expenses due to expanded clinical development and commercial preparation activities.